A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

Abstract
Prophylaxis against Pneumocystis carinii pneumonia is indicated in patients with human immunodeficiency virus (HIV) infection who have less than 200 CD4 cells per cubic millimeter and in those with a history of P. carinii pneumonia. However, it is not clear whether prophylaxis can be safely discontinued after CD4 cell counts increase in response to highly active antiretroviral therapy.

This publication has 31 references indexed in Scilit: